Annual CFF
$18.37 M
+$11.82 M+180.41%
31 December 2023
Summary:
Rigel Pharmaceuticals annual cash flow from financing activities is currently $18.37 million, with the most recent change of +$11.82 million (+180.41%) on 31 December 2023. During the last 3 years, it has risen by +$5.80 million (+46.11%). RIGL annual CFF is now -87.06% below its all-time high of $141.98 million, reached on 31 December 2011.RIGL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$9.84 M
-$9.09 M-1208.78%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly cash flow from financing activities is currently -$9.84 million, with the most recent change of -$9.09 million (-1208.78%) on 30 September 2024. Over the past year, it has dropped by -$8.97 million (-1032.57%). RIGL quarterly CFF is now -106.96% below its all-time high of $141.39 million, reached on 30 June 2011.RIGL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$12.62 M
-$8.97 M-246.04%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM cash flow from financing activities is currently -$12.62 million, with the most recent change of -$8.97 million (-246.04%) on 30 September 2024. Over the past year, it has dropped by -$28.41 million (-179.95%). RIGL TTM CFF is now -106.82% below its all-time high of $185.15 million, reached on 31 March 2008.RIGL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +180.4% | -1032.6% | -179.9% |
| 3 y3 years | +46.1% | -3692.0% | -120.3% |
| 5 y5 years | -74.5% | -200.4% | -207.2% |
RIGL Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -70.7% | +180.4% | -151.5% | at low | -118.2% | at low |
| 5 y | 5 years | -74.5% | +180.4% | -116.6% | at low | -118.2% | at low |
| alltime | all time | -87.1% | +4568.9% | -107.0% | at low | -106.8% | at low |
Rigel Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.84 M(+1208.8%) | -$12.62 M(+246.0%) |
| June 2024 | - | -$752.00 K(-70.1%) | -$3.65 M(+11.6%) |
| Mar 2024 | - | -$2.51 M(-616.9%) | -$3.27 M(-117.8%) |
| Dec 2023 | $18.37 M(+180.4%) | $486.00 K(-155.9%) | $18.37 M(+16.4%) |
| Sept 2023 | - | -$869.00 K(+133.0%) | $15.79 M(-28.8%) |
| June 2023 | - | -$373.00 K(-102.0%) | $22.16 M(+31.3%) |
| Mar 2023 | - | $19.12 M(-1012.4%) | $16.88 M(+157.6%) |
| Dec 2022 | $6.55 M(-89.5%) | -$2.10 M(-138.0%) | $6.55 M(-32.7%) |
| Sept 2022 | - | $5.51 M(-197.3%) | $9.73 M(+116.5%) |
| June 2022 | - | -$5.66 M(-164.4%) | $4.49 M(-93.5%) |
| Mar 2022 | - | $8.80 M(+710.8%) | $69.38 M(+10.7%) |
| Dec 2021 | $62.67 M(+398.6%) | $1.08 M(+296.0%) | $62.67 M(+0.7%) |
| Sept 2021 | - | $274.00 K(-99.5%) | $62.26 M(+0.4%) |
| June 2021 | - | $59.22 M(+2724.0%) | $62.03 M(+365.3%) |
| Mar 2021 | - | $2.10 M(+214.4%) | $13.33 M(+6.1%) |
| Dec 2020 | $12.57 M(+10.6%) | $667.00 K(+1182.7%) | $12.57 M(-0.2%) |
| Sept 2020 | - | $52.00 K(-99.5%) | $12.60 M(-43.6%) |
| June 2020 | - | $10.52 M(+687.1%) | $22.34 M(+76.2%) |
| Mar 2020 | - | $1.34 M(+92.5%) | $12.69 M(+11.6%) |
| Dec 2019 | $11.37 M(-84.2%) | $694.00 K(-92.9%) | $11.37 M(-3.4%) |
| Sept 2019 | - | $9.80 M(+1044.7%) | $11.77 M(+351.7%) |
| June 2019 | - | $856.00 K(+5250.0%) | $2.61 M(-96.3%) |
| Mar 2019 | - | $16.00 K(-98.5%) | $69.90 M(-2.8%) |
| Dec 2018 | $71.89 M(-38.9%) | $1.10 M(+73.1%) | $71.89 M(-48.0%) |
| Sept 2018 | - | $635.00 K(-99.1%) | $138.16 M(-1.9%) |
| June 2018 | - | $68.15 M(+3288.8%) | $140.86 M(+84.7%) |
| Mar 2018 | - | $2.01 M(-97.0%) | $76.28 M(-35.2%) |
| Dec 2017 | $117.69 M(+367.3%) | $67.37 M(+1918.8%) | $117.69 M(+124.8%) |
| Sept 2017 | - | $3.34 M(-6.3%) | $52.36 M(-15.8%) |
| June 2017 | - | $3.56 M(-91.8%) | $62.20 M(-9.3%) |
| Mar 2017 | - | $43.42 M(+2033.9%) | $68.60 M(+172.4%) |
| Dec 2016 | $25.18 M(+257.1%) | $2.04 M(-84.6%) | $25.18 M(-13.4%) |
| Sept 2016 | - | $13.18 M(+32.3%) | $29.07 M(+81.8%) |
| June 2016 | - | $9.96 M(>+9900.0%) | $15.99 M(+127.1%) |
| Mar 2016 | - | $4000.00(-99.9%) | $7.04 M(-0.2%) |
| Dec 2015 | $7.05 M(+502.8%) | $5.93 M(+5946.9%) | $7.05 M(+338.9%) |
| Sept 2015 | - | $98.00 K(-90.3%) | $1.61 M(+6.1%) |
| June 2015 | - | $1.01 M(+5852.9%) | $1.51 M(+30.2%) |
| Mar 2015 | - | $17.00 K(-96.5%) | $1.16 M(-0.6%) |
| Dec 2014 | $1.17 M(+11.3%) | $480.00 K(+9500.0%) | $1.17 M(+27.3%) |
| Sept 2014 | - | $5000.00(-99.2%) | $919.00 K(+0.5%) |
| June 2014 | - | $661.00 K(+2654.2%) | $914.00 K(-15.0%) |
| Mar 2014 | - | $24.00 K(-89.5%) | $1.07 M(+2.3%) |
| Dec 2013 | $1.05 M(-99.2%) | $229.00 K(>+9900.0%) | $1.05 M(-99.2%) |
| Sept 2013 | - | $0.00(-100.0%) | $137.35 M(-0.9%) |
| June 2013 | - | $822.00 K(>+9900.0%) | $138.54 M(-0.0%) |
| Mar 2013 | - | $0.00(-100.0%) | $138.61 M(-0.4%) |
| Dec 2012 | $139.09 M | $136.53 M(>+9900.0%) | $139.09 M(+4067.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $1.20 M(+35.1%) | $3.34 M(+54.3%) |
| June 2012 | - | $885.00 K(+81.4%) | $2.16 M(-98.5%) |
| Mar 2012 | - | $488.00 K(-36.5%) | $142.67 M(+0.5%) |
| Dec 2011 | $141.98 M(>+9900.0%) | $769.00 K(+3561.9%) | $141.98 M(+0.2%) |
| Sept 2011 | - | $21.00 K(-100.0%) | $141.72 M(+0.0%) |
| June 2011 | - | $141.39 M(<-9900.0%) | $141.66 M(>+9900.0%) |
| Mar 2011 | - | -$199.00 K(-139.3%) | $858.00 K(+4.6%) |
| Dec 2010 | $820.00 K(-99.2%) | $506.00 K(-1588.2%) | $820.00 K(-7.9%) |
| Sept 2010 | - | -$34.00 K(-105.8%) | $890.00 K(-99.1%) |
| June 2010 | - | $585.00 K(-346.8%) | $102.50 M(+0.2%) |
| Mar 2010 | - | -$237.00 K(-141.1%) | $102.26 M(+0.1%) |
| Dec 2009 | $102.16 M(-22.6%) | $576.00 K(-99.4%) | $102.16 M(-1.0%) |
| Sept 2009 | - | $101.57 M(>+9900.0%) | $103.16 M(+4966.8%) |
| June 2009 | - | $346.00 K(-202.4%) | $2.04 M(-37.4%) |
| Mar 2009 | - | -$338.00 K(-121.4%) | $3.25 M(-97.5%) |
| Dec 2008 | $131.99 M(+132.5%) | $1.58 M(+253.7%) | $131.99 M(-1.9%) |
| Sept 2008 | - | $447.00 K(-71.4%) | $134.56 M(+0.5%) |
| June 2008 | - | $1.56 M(-98.8%) | $133.90 M(-27.7%) |
| Mar 2008 | - | $128.40 M(+2991.7%) | $185.15 M(+226.1%) |
| Dec 2007 | $56.78 M(+1902.0%) | $4.15 M(-2013.8%) | $56.78 M(+6.9%) |
| Sept 2007 | - | -$217.00 K(-100.4%) | $53.09 M(-2.1%) |
| June 2007 | - | $52.82 M(>+9900.0%) | $54.24 M(+2426.2%) |
| Mar 2007 | - | $21.00 K(-95.6%) | $2.15 M(-24.3%) |
| Dec 2006 | $2.84 M(-97.3%) | $472.00 K(-49.0%) | $2.84 M(-84.6%) |
| Sept 2006 | - | $925.00 K(+26.9%) | $18.41 M(-81.4%) |
| June 2006 | - | $729.00 K(+2.7%) | $99.03 M(+0.4%) |
| Mar 2006 | - | $710.00 K(-95.6%) | $98.67 M(-4.8%) |
| Dec 2005 | $103.61 M(+59.8%) | $16.05 M(-80.3%) | $103.61 M(+11.0%) |
| Sept 2005 | - | $81.54 M(>+9900.0%) | $93.35 M(+622.1%) |
| June 2005 | - | $371.00 K(-93.4%) | $12.93 M(+3.4%) |
| Mar 2005 | - | $5.64 M(-2.5%) | $12.50 M(-80.7%) |
| Dec 2004 | $64.83 M(+22.7%) | $5.79 M(+416.0%) | $64.83 M(+10.3%) |
| Sept 2004 | - | $1.12 M(-2217.0%) | $58.75 M(-11.1%) |
| June 2004 | - | -$53.00 K(-100.1%) | $66.12 M(-40.5%) |
| Mar 2004 | - | $57.97 M(<-9900.0%) | $111.16 M(+110.4%) |
| Dec 2003 | $52.83 M(+75.6%) | -$289.00 K(-103.4%) | $52.83 M(+1.2%) |
| Sept 2003 | - | $8.48 M(-81.1%) | $52.23 M(+20.7%) |
| June 2003 | - | $44.99 M(<-9900.0%) | $43.28 M(-3943.7%) |
| Mar 2003 | - | -$357.00 K(-60.1%) | -$1.13 M(-103.7%) |
| Dec 2002 | $30.08 M(-7419.7%) | -$894.00 K(+93.5%) | $30.08 M(-2.0%) |
| Sept 2002 | - | -$462.00 K(-178.7%) | $30.69 M(+0.6%) |
| June 2002 | - | $587.00 K(-98.1%) | $30.49 M(-0.7%) |
| Mar 2002 | - | $30.85 M(<-9900.0%) | $30.71 M(-7572.3%) |
| Dec 2001 | -$411.00 K(-100.7%) | -$290.00 K(-56.0%) | -$411.00 K(+239.7%) |
| Sept 2001 | - | -$659.00 K(-181.7%) | -$121.00 K(-122.5%) |
| June 2001 | - | $807.00 K(-400.0%) | $538.00 K(-300.0%) |
| Mar 2001 | - | -$269.00 K | -$269.00 K |
| Dec 2000 | $62.36 M(+453.8%) | - | - |
| Dec 1999 | $11.26 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual CFF year-on-year change?
- What is Rigel Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly CFF year-on-year change?
- What is Rigel Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM CFF year-on-year change?
What is Rigel Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of RIGL is $18.37 M
What is the all time high annual CFF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual cash flow from financing activities is $141.98 M
What is Rigel Pharmaceuticals annual CFF year-on-year change?
Over the past year, RIGL annual cash flow from financing activities has changed by +$11.82 M (+180.41%)
What is Rigel Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of RIGL is -$9.84 M
What is the all time high quarterly CFF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly cash flow from financing activities is $141.39 M
What is Rigel Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, RIGL quarterly cash flow from financing activities has changed by -$8.97 M (-1032.57%)
What is Rigel Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of RIGL is -$12.62 M
What is the all time high TTM CFF for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM cash flow from financing activities is $185.15 M
What is Rigel Pharmaceuticals TTM CFF year-on-year change?
Over the past year, RIGL TTM cash flow from financing activities has changed by -$28.41 M (-179.95%)